PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA (pembrolizumab)
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) has announced updated interim data from the VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 in combination with Merck's (NYSE:MRK) KEYTRUDA in patients with HPV16-positive head and neck squamous cell carcinoma. The 24-month survival rate was 74% in immune checkpoint inhibitor naive patients.
October 03, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA was used in combination with PDS Biotech's PDS0101 in a successful clinical trial, which could positively impact Merck's stock.
Merck's KEYTRUDA was used in combination with PDS Biotech's PDS0101 in a successful clinical trial. This could lead to increased investor confidence in Merck and a potential increase in its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Positive interim data from the VERSATILE-002 Phase 2 clinical trial could boost investor confidence in PDS Biotech.
The positive interim data from the clinical trial indicates that PDS Biotech's PDS0101 in combination with Merck's KEYTRUDA is effective in treating HPV16-positive head and neck squamous cell carcinoma. This could lead to increased investor confidence in PDS Biotech and a potential increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100